文献速递临床试验与 GCP流行病学与生物统计

阿托伐他汀与未使用他汀治疗对无明确他汀适应证的急性心源性栓塞性卒中患者主要临床事件的影响:STACE试验方案

Effect of atorvastatin versus no Statin Treatment on major clinical events in Acute CardioEmbolic stroke patients without a definite indication for statin therapy: protocol for the STACE trial.
PubMed 文献 · Trials · 2025-09-26

STACE试验为基于注册的多中心、前瞻性、随机、开放标签、盲法终点研究,旨在评估无明确他汀适应证的急性心源性栓塞性卒中患者使用他汀的疗效与安全性。患者按1:1随机分为他汀使用组(阿托伐他汀≥10 mg)与非使用组,计划招募1036例,主要终点为索引卒中后3个月内主要临床事件(卒中复发、心肌梗死、全因死亡的复合终点)。

要点

  • STACE试验针对无明确他汀适应证的急性心源性栓塞性卒中患者,比较他汀使用与非使用的疗效与安全性。
  • 他汀使用组接受阿托伐他汀10 mg或更高剂量,研究期间持续用药。
  • 主要终点为索引卒中后3个月内卒中复发、心肌梗死和全因死亡的复合终点。

核心结论

  • 本研究旨在探讨无明确适应证的急性心源性栓塞性卒中患者使用他汀治疗的潜在获益,以协助卒中医生确定此类患者他汀的合理使用。

研究设计与样本

  • 基于注册的多中心、前瞻性、随机、开放标签、盲法终点(PROBE)研究。
  • 计划招募1036例参与者,按1:1随机分为他汀使用组与非使用组;他汀使用组接受阿托伐他汀剂量10 mg或更高,整个研究期间持续用药。
  • 样本量按检测43%的相对风险降低、80%把握度、双侧α误差0.05、并考虑10%失访计算。

主要发现

  • 主要终点为索引卒中后3个月内主要临床事件的发生,即卒中复发、心肌梗死和全因死亡的复合终点。
  • 次要疗效终点包括卒中复发、全因死亡、血管性死亡和主要血管事件。

临床怎么用

  • 本研究将协助卒中医生为无指南适应证的急性心源性栓塞性卒中患者确定他汀治疗的适当使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence supporting the use of statin therapy to reduce stroke recurrence and cardiovascular events in acute cardioembolic stroke (CES) patients without atherosclerosis is limited. Past observational studies have been hampered by selection bias and unmeasured confounding factors. This study aims to investigate the potential benefits of statin therapy in acute CES patients without established indications through a registry-based, randomized clinical trial. METHODS: This is a registry-based, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) study designed to evaluate the efficacy and safety of statin therapy in acute CES patients without established indications for statin use. Patients will be randomly assigned (1:1) to either statin users or non-users, with statin users receiving atorvastatin at a dose of 10 mg or higher throughout the study period. We plan to recruit 1036 participants to detect a relative risk reduction of 43% with 80% power and a two-sided alpha error of 0.05, accounting for a 10% loss to follow-up. The primary outcome is the occurrence of a major clinical event, defined as a composite of stroke recurrence, myocardial infarction, and all-cause mortality within 3 months after the index stroke. The secondary efficacy outcomes include (1) stroke recurrence, (2) all-cause mortality, (3) vascular death, and (4) major vascular events. DISCUSSION: This study will assist stroke physicians in determining the appropriate use of statin therapy for acute CES patients who do not have guideline-based indications. TRIAL REGISTRATION: CRIS Registration Number: KCT0006806. Registered on November 29, 2021. URL: https://cris.nih.go.kr/cris.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Park HK, Kim JY, Hong KS, et al. Effect of atorvastatin versus no Statin Treatment on major clinical events in Acute CardioEmbolic stroke patients without a definite indication for statin therapy: protocol for the STACE trial. Trials. 2025. PMID: 41013792. doi:10.1186/s13063-025-09097-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。